POXEL, the diabetes drug development specialist, aims to find innovative solutions for metabolic diseases management

Poxel is a diabetes drug development company, aiming at progressing promising assets for metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before partnering with pharmaceutical companies.

Its pipeline consists in innovative products with original mechanism of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies.

The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the total product life cycle. Poxel’s team performs and coordinates all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on metabolic diseases.

A focused and streamlined development of the company assets will ensure successful partnerships.

Poxel’s team is advised by a rewarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe.
Poxel raised €16 million from a strong syndicate of investors in July 2010 (read the press release in the "Recent news" section on your right hand side).